Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986253 in severe COVID-19
NCT04347226Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing BMS-986253 with Standard of Care (2 arms). Primary endpoint: Time to Improvement in the 7-point Ordinal Scale up to 10.5 months. Started Apr 2020; status: terminated.
02
Drugs
adakitug
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04347226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347226.